Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEI-01 in Advanced Solid Tumors and AML
NCT05226468Phase 1Unknown
- Sponsor
- New Epsilon Innovation Limited
- Start
- Apr 2022
- Primary completion
- Jan 2024
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adargiminase in solid tumor (advanced stage) and acute myeloid leukemia (AML), sponsored by New Epsilon Innovation Limited. Primary endpoints: Maximum Tolerated Dose / Recommended Dose Level at 12 months, Occurrence of Dose Limiting Toxicity and 2 more. Status: unknown.
02
Drugs
adargiminase
03
Conditions
solid tumor (advanced stage)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05226468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05226468.